• Active Substance: Sotaglifozin
  • Name: Zynquista®
  • Therapeutic area: Type-1 diabetes mellitus
  • Pharmaceutical company: Sanofi S.A.


Time table:

  • Publication of project plan: 05.03.2019
  • Publication of final assessment: 07.06.2019


Assessment information:

  • Title: Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed to achieve adequate glycaemic control despite optimal insulin therapy
  • Author/Co-Author: TLV (Sweden), ZIN (Netherlands), NCPE (Ireland)
  • Dedicated Reviewers: AEMPS (Spain), SNHTA (Switzerland), NVD (Latvia), INFARMED (Portugal), AOTMiT (Poland)
  • Information retrieval: N.N.
  • Observer: HIS (UK), EOF (Greece)

G-BA assessment not available
Reason: Sotaglifozin was not launched in Germany.